Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma.

JAMA dermatology - 1 Jun 2017

Knepper Todd C, Freeman Morganna L, Gibney Geoffrey T, McLeod Howard L, Russell Jeffery S

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Basal Cell
Share to DNA, Neoplasm
Share to Indazoles
Share to Pyrimidines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Receptors, Vascular Endothelial Growth Factor

Share to Skin Neoplasms

Share to Sulfonamides

Share to Vascular Endothelial Growth Factor Receptor-2

Source

Identifiers

PMID: 28384659
DOI: 10.1001/jamadermatol.2017.0187

Genes

KDR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma.PMID 28384659Read ↗

Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.Semantic proximity Read ↗

Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.Semantic proximity Read ↗

RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to CabozantinibSemantic proximity Read ↗

Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine TherapySemantic proximity Read ↗

Mutated ERBB4: a novel drug target in metastatic melanoma?Semantic proximity Read ↗

613MO A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) & BRAF-altered solid tumorsSemantic proximity Read ↗

Durable Disease Control with Regorafenib in a Patient with Metastatic KIT-Mutated Colorectal Cancer.Semantic proximity Read ↗

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.Semantic proximity Read ↗

Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.Semantic proximity Read ↗

Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.Semantic proximity Read ↗

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.